Special Issue

The Molecular Pathways Involved in Atopic Dermatitis: Implications for Targeted Therapy

Message from the Guest Editor

Atopic dermatitis is one of the most common immune-mediated diseases worldwide, and its prevalence has increased in recent decades. Today, atopic dermatitis is recognized as a disease occurring in predisposed individuals with a compromised skin barrier function. After decades of treatment that is reliant on classical immunosuppressive drugs, atopic dermatitis is now more adequately treated with targeted therapies that aim to block or modulate the key inflammatory pathways responsible for the persistent skin inflammation seen in severe atopic dermatitis. Current standard therapies block the signaling axis of Interleukin (IL)-4 and IL-13, Janus kinases (JAK), and IL-31. Despite this significant advancement, a more detailed understanding of the inflammatory pathways involved in atopic dermatitis is crucial for various objectives, including the discovery of severity markers, clinical response markers, and therapeutic failure markers. This Special Issue aims to encourage studies that uncover the inflammatory pathways of atopic dermatitis and ultimately shed light on the development of new clinical and laboratory markers, as well as new therapeutic targets.

Guest Editor

Prof. Dr. Ciro Martins Gomes
Dermatology Department, University of Brasília (UNB), Brasilia, Brazil

Deadline for manuscript submissions

30 October 2025

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/240221

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/cimb

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.